Copyright
©The Author(s) 2015.
World J Gastroenterol. May 28, 2015; 21(20): 6236-6245
Published online May 28, 2015. doi: 10.3748/wjg.v21.i20.6236
Published online May 28, 2015. doi: 10.3748/wjg.v21.i20.6236
Table 7 Frequency of rejection, plasma cell hepatitis and fibrosing cholestatic hepatitis n (%)
| Pre-anti viral treatmentn = 153 | On-anti viral treatmentn =90 | Post-anti viral treatmentn = 89 | |
| Rejection | 39 (25) | 12 (13)1 | 8 (9) |
| ACR | 39 (25) | 10 (11) | 7 (8) |
| CDR | 0 | 5 (6) | 1 (1) |
| Plasma cell hepatitis | 7 (5) | 11 (12) | 12 (13) |
| Fibrosing cholestatic hepatitis | 7 (5) | 5 (6) | 1 (1) |
- Citation: Lim KB, Sima HR, Fiel MI, Khaitova V, Doucette JT, Chernyiak M, Ahmad J, Bach N, Chang C, Grewal P, Kim-Schluger L, Liu L, Odin J, Perumalswami P, Florman SS, Schiano TD. Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus. World J Gastroenterol 2015; 21(20): 6236-6245
- URL: https://www.wjgnet.com/1007-9327/full/v21/i20/6236.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i20.6236